This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Lindsay, R. L. Articles by Aman, M. G. Search for Related Content PubMed PubMed Citation Articles by Lindsay, R. L. Articles by Aman, M. G. Social Bookmarking                   What's this?

Discontinuation of Risperidone and Reversibility of Weight Gain in Children with Disruptive Behavior Disorders

The Nisonger Center for Mental Retardation, Ohio State University, Columbus, Ohio

Sarah Leone, MA

The Nisonger Center for Mental Retardation, Ohio State University, Columbus, Ohio

Michael G. Aman, PhD

The Nisonger Center for Mental Retardation, Ohio State University, Columbus, Ohio

Although atypical antipsychotics generally have a good side effect profile and are clinically very effective, weight gain and associated problems accompany their use. The authors followed up 14 subjects who were in studies of risperidone for management of disruptive behavior disorders. The subjects exited after a mean exposure of 8.9 months because of excessive weight gain, or excessive appetite, or insufficient clinical response. Weight was monitored for the full cohort before risperidone treatment, at termination, and (for various subgroups) at 3, 9-12, and 24 months after termination. Analysis of standardized weight scores in relation to standardized BMI scores suggested marked similarity between them at all time points. Comparison of standardized weights at time of drug termination with 3, 9-12, and 24 months after termination indicated that weight gain during risperidone treatment is reversible (i.e., significantly less weight after risperidone was discontinued) at all time points after termination. Furthermore, standardized weight at 12 and 24 months after discontinuation of risperidone was not distinguishable from standardized weight before risperidone. The prospect of reversibility may provide some comfort for clinicians and parents alike, but far more data are needed before an assumption can be made that this is the case for all children. The authors provide several recommendations for clinicians and researchers working with atypical antipsychotics.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?